• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The effect of butylphthalide on improving the neurological function of patients with acute anterior circulation cerebral infarction after mechanical thrombectomy
Medicine (Baltimore). 2023 Aug 25;102(34):e34616. doi: 10.1097/MD.0000000000034616.ABSTRACTButylphthalide can improve blood circulation in patients with acute cerebral infarction. Complement 3a receptor 1 (C3aR1) is involved in the regulation of innate immune response and pathogen monitoring, which is closely related to the pathophysiological processes of breast cancer, neurogenesis and lipid catabolism. Our study explored the therapeutic effect of butylphthalide on improving the neurological function of patients with acute anterior circulation cerebral infarction after mechanical thrombectomy, and evaluated the correlatio...
Source: Cancer Control - September 1, 2023 Category: Cancer & Oncology Authors: Xinghua Wang Xinchi Luan Zhigang Yang Source Type: research

Revealing the concealed: A tribute to Donald L. Morton, MD
Clin Exp Metastasis. 2023 Jul 31. doi: 10.1007/s10585-023-10223-9. Online ahead of print.ABSTRACTDonald L. Morton, MD, epitomized one of America's dream scenarios: a person evolving from the humblest of origins to become an international celebrity in his profession, leading the world in the discipline of surgical oncology. His pioneering accomplishments in various roles have been well documented. Scientists, clinicians, students, and patients benefited from his contributions to the management of malignant diseases, particularly melanoma. His many attributes in pursuing the goal to cure malignant diseases are well known. Br...
Source: Clinical Breast Cancer - July 31, 2023 Category: Cancer & Oncology Authors: S David Nathanson Ian Wood Source Type: research

Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial
Lancet Oncol. 2023 Jan 6:S1470-2045(22)00739-2. doi: 10.1016/S1470-2045(22)00739-2. Online ahead of print.ABSTRACTBACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in germline BRCA1 or BRCA2 (BRCA1/2) mutation-associated metastatic breast cancer. However, studies evaluating PARP inhibitors plus platinum-based chemotherapy in germline BRCA1/2-wildtype triple-negative breast cancer are scarce. A large proportion of germline BRCA1/2-wildtype triple-negative breast cancer shows homologous recombination deficiency (HRD), resulting in a BRCA-like phenotype that might render sensitivity to PARP inhibitors. T...
Source: Ann Oncol - January 9, 2023 Category: Cancer & Oncology Authors: Eve Rodler Priyanka Sharma William E Barlow Julie R Gralow Shannon L Puhalla Carey K Anders Lori Goldstein Debu Tripathy Ursa A Brown-Glaberman Thu-Tam Huynh Christopher S Szyarto Andrew K Godwin Harsh B Pathak Elizabeth M Swisher Marc R Radke Kirsten M T Source Type: research

The Role of Safety-Net Hospitals in Reducing Disparities in Breast Cancer Care
Ann Surg Oncol. 2022 Mar 31. doi: 10.1245/s10434-022-11576-3. Online ahead of print.ABSTRACTAdvances in breast cancer screening and systemic therapies have been credited with profound improvements in breast cancer outcomes; indeed, 5-year relative survival rate approaches 91% in the USA (U.S. National Institutes of Health NCI. SEER Training Modules, Breast). While breast cancer mortality has been declining, oncologic outcomes have not improved equally among all races and ethnicities. Many factors have been implicated in breast cancer disparities; chief among them is limited access to care which contributes to lower rates o...
Source: Ann Oncol - March 31, 2022 Category: Cancer & Oncology Authors: Angelena Crown Kalpana Ramiah Bruce Siegel Kathie-Ann Joseph Source Type: research

Recent Advances on Therapeutic Peptides for Breast Cancer Treatment.
Abstract Breast cancer is a heterogeneous malignancy which is the second cause of mortality among women in the world. Increasing the resistance to anti-cancer drugs in breast cancer cells persuades researchers to search the novel therapies approaches for the treatment of the malignancy. Among the novel methods, therapeutic peptides which target and disrupt tumor cells have been of great interest. Therapeutic peptides are short amino acids monomer chains with high specificity to bind and modulate a protein interaction of interest. Several advantages of peptides such as specific binding on tumor cells surface, low m...
Source: Current Protein and Peptide Science - November 17, 2020 Category: Biochemistry Authors: Beheshtirouy S, Mirzaei F, Eyvazi S, Tarhriz V Tags: Curr Protein Pept Sci Source Type: research

Informatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives
Joseph D. Romano1,2,3,4 and Nicholas P. Tatonetti1,2,3,4* 1Department of Biomedical Informatics, Columbia University, New York, NY, United States 2Department of Systems Biology, Columbia University, New York, NY, United States 3Department of Medicine, Columbia University, New York, NY, United States 4Data Science Institute, Columbia University, New York, NY, United States The discovery of new pharmaceutical drugs is one of the preeminent tasks—scientifically, economically, and socially—in biomedical research. Advances in informatics and computational biology have increased productivity at many ...
Source: Frontiers in Genetics - April 29, 2019 Category: Genetics & Stem Cells Source Type: research

Physical activity participation and the risk of chronic diseases among South Asian adults: protocol for a systematic review and meta-analysis
DiscussionThis review will summarise the strength of the association between physical activity and selected chronic diseases and their markers among South Asian adults 40  years or older. The findings will provide an evidence base to guide public health policy and interventions in the South Asian region and to inform future research to address the rising burden of chronic diseases.Systematic review registrationPROSPEROCRD42018096505
Source: Systematic Reviews - October 30, 2018 Category: International Medicine & Public Health Source Type: research

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight The MAReport: read the Summer/Fall 2018 issue of the MAReport newsletter! This quarter, All of Us Community Engagement Coordinator Veronica Leigh Milliner talks about opportunities to incorporate genetics into health programming in her article, “Your Family, Your History, Your Health: Genetics Resources.” New Funding Opportunity: NNLM MAR is pleased to announce the availability of funding through NLM’s partnership with the NIH All of Us Research Program. We are now accepting applications for the NNLM All of...
Source: NN/LM Middle Atlantic Region Blog - October 12, 2018 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

Top Companies in Genomics
From portable genome sequencers until genetic tests revealing distant relations with Thomas Jefferson, genomics represents a fascinatingly innovative area of healthcare. As the price of genome sequencing has been in free fall for years, the start-up scene is bursting from transformative power. Let’s look at some of the most amazing ventures in genomics! The amazing journey of genome sequencing Genome sequencing has been on an amazing scientific as well as economic journey for the last three decades. The Human Genome Project began in 1990 with the aim of mapping the whole structure of the human genome and sequencing it. ...
Source: The Medical Futurist - May 30, 2017 Category: Information Technology Authors: nora Tags: Genomics Personalized Medicine AI artificial intelligence bioinformatics cancer DNA dna testing DTC gc3 genetic disorders genetics genome sequencing personal genomics precision medicine Source Type: blogs

Compound Shows Promise as Next-Generation Prostate Cancer Therapy
Contact: Sarah Avery Phone: 919-660-1306 Email:sarah.avery@duke.eduhttps://www.dukehealth.orgEMBARGOED FOR RELEASE until 11 a.m. (ET) Monday, Aug. 8, 2016DURHAM, N.C. -- In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.The potential foundation for a next-generation therapy, called tetraaryl cyclobutane, or CB, is being studied as an option for prostate tumors that have grown resistant to current anti-androgen drugs, notably enzalutamide.“Prostate cancer is the most p...
Source: DukeHealth.org: Duke Health Features - August 8, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news

Pages: 1  2